Evaluation of PillCam® Express Capsule Endoscopy Delivery System
NCT ID: NCT01088646
Last Updated: 2020-10-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2009-10-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PillCam® Platform With the PillCam Crohn's Disease Capsule
NCT01631435
Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.
NCT03241368
Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease
NCT02025777
PillCam SBC System Functionality in Established and Suspected IBD Patients
NCT02742714
Evaluation of Small Bowel Colon Capsule for Bowel Visualization in Crohn's Disease Patients
NCT01233310
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The PillCam™ SB capsule to be used in this study was cleared by the FDA in August 2001 for small bowel evaluation. It has been ingested to date by more than 1,000,000 people worldwide and is well accepted by subjects and physicians as well as the professional societies.
Further details of the PillCam®Express Capsule Endoscopy Delivery System can be found in the device description section.
This study is designed to evaluate the performance and safety of the Capsule Endoscopy Delivery System in subjects indicated to undergo a standard Esophagogastroduodenoscopy (EGD) endoscopy
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DEVICE_FEASIBILITY
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PillCam® Express Capsule Endoscopy Delivery System
The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.
Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.
The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject scheduled for EGD endoscopy with a 2.8 mm (or greater) working channel
Exclusion Criteria
* Subject has history of UGI tract surgery (e.g., Billroth I, Billroth II, esophagectomy, gastrectomy, bariatric procedure)
* Presence of an electro-medical device (pacemaker or internal cardiac defibrillator)
* Subject is pregnant
* Subject is expected to undergo a MRI examination within 7 days after ingestion of the capsule
* Subject has known allergy to conscious sedation medications
* Subject or legal guardian is not able to provide written informed consent
2 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic - MITG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Leighton, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Peter Legnani, MD
Role: PRINCIPAL_INVESTIGATOR
Private Practice New York, New York
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Digestive Disorders Center, P. C.
Huntsville, Alabama, United States
Alabama Liver and Digestive Specialists
Montgomery, Alabama, United States
RANY -Research Associates of New York (NY Gastroenterology Associates)
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RD-300
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.